reports
- ING Helpdesk
- ING Helpdesk
- ING Helpdesk
Benelux Morning Notes
Ahold Delhaize: 2Q25 pre-close call feedback. Azelis: Attractive acquisition in personal care Italy. Econocom: Two UK/Ireland AV acquisitions disclosed. Staffing: Better French volumes in May even with easier comps, June outlook sluggish. Staffing: Dutch figs Period 6 volume and revenues weaker on tougher comps. UCB: Trump threatens a 200% tariff on pharmaceutical products
- ING Helpdesk
- ING Helpdesk
- Guy Sips
- Hilde Van Boxstael
- Kristof Samoy
- Livio Luyten
- Michiel Declercq
- Thibault Leneeuw
- Thomas Vranken
- Wim Hoste
- Wim Lewi
Dynamic Top Pick List Update July: Removing Fagron and Melexis, Adding...
Since the last publication of our Dynamic Top Pick List on 5 June 2025, our selection has seen again a nice outperformance versus the reverence indices (AEX, Bel20 and Eurostoxx50) of on average 3.3%. Our July update brings 3 adjustments to the list : Since being added to the list in December 2024, Fagron's share price has surged +/-22%, driven by strong Q1 2025 results and robust growth across all regions. Fagron reaffirmed its FY25 guidance and unveiled its “Compounding for Growth” strategy, ...
- Jacob Mekhael
- Livio Luyten
- Michiel Declercq
- Thomas Couvreur
- Thomas Vranken
- Wim Hoste
- Thomas Vranken
Biotalys The planned Evoca-tion of a first US approval
Biotalys is a Belgian AgTech company developing protein-based biocontrols through its proprietary Agrobody Foundry platform. The company aims to replace traditional chemical pesticides with safer, sustainable alternatives. The company recently guided for market approval in the US for its lead product Evoca by the end of September 2025, which would reflect an important value inflection point for the company. We have updated our model, and taking into account the expected near-term trigger, raise ...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Thomas Couvreur
Arbitral Tribunal acting under ICC Rules of Arbitration issues final a...
Arbitral Tribunal acting under ICC Rules of Arbitration issues final award in an arbitration between Agfa-Gevaert and the insolvency receiver of AgfaPhoto GmbH June 27, 2025 - 1.45 PM CETRegulated information – Contains inside information Arbitral Tribunal acting under ICC Rules of Arbitration issues final award in an arbitration between Agfa-Gevaert and the insolvency receiver of AgfaPhoto GmbH Mortsel, Belgium – June 27, 2025 – 1.45 PM CETAn Arbitral Tribunal acting under the International Chamber of Commerce (ICC) Rules of Arbitration has render...
Tribunaal handelend volgens het ICC-arbitragereglement velt finale sen...
Tribunaal handelend volgens het ICC-arbitragereglement velt finale sententie in arbitragegeschil tussen Agfa-Gevaert en de curator van AgfaPhoto GmbH 27 juni 2025 – 13u45Gereglementeerde informatie – Bevat voorwetenschap Tribunaal handelend volgens het ICC-arbitragereglement velt finale sententie in arbitragegeschil tussen Agfa-Gevaert en de curator van AgfaPhoto GmbH Mortsel, België – 27 juni 2025 – 13u45 Een Tribunaal dat handelt volgens het Arbitragereglement van de Internationale Kamer van Koophandel (ICC) heeft een finale sententie geveld in een laatste arbitragegeschil met een moge...
- ING Helpdesk
- Hilde Van Boxstael
- Thibault Leneeuw
- Thomas Couvreur
- Thomas Vranken
- Wim Hoste
- Thomas Vranken
UCB FIRST LOOK: Fintepla scores Phase 3 win in third epileptic indicat...
UCB announced positive Phase 3 results for Fintepla in treating CDKL5 deficiency disorder (CDD), a rare and severe early-onset epileptic condition with limited treatment options. The randomized, placebo-controlled study in patients aged 1–35 met its primary and secondary endpoints, showing a significant reduction in countable motor seizures and a favourable safety profile. UCB plans to announce the full dataset at an upcoming conference and seek regulatory approval promptly. This marks Fintepla'...
- Dominic Rose
- Naresh Chouhan
UCB - Bimzelx Consensus for 2025 Too Low
We are 28% above cons. US Bimzelx sales for H125 with Bimzelx sales momentum being the most important factor for the UCB investment thesis. Unlike the early days for US obesity, this is one of the most complex dynamics we have contended with when forecasting sales. There are multiple unknowns that we have sought to model (net price per scrip, net avg. price by indication, 2024 volume, volume growth by payer & incremental discounts to unlock that volume growth). As a result of our analysis, we in...
- ING Helpdesk
- Guy Sips
- Hilde Van Boxstael
- Wim Lewi
- ING Helpdesk
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Michiel Declercq
- Thomas Vranken
- Wim Lewi
- Wim Lewi
Dollar Weakness The impact on our Benelux Coverage
In general, a weaker USD has a negative impact on Benelux stocks, particularly for companies with significant exports to the US. In this note we selected a list of companies with high US export exposure and we examine the potential impact on FY25 earninings. On top of the weak dollar, rising trade tensions or the introduction of tariffs further harm Benelux exporters. As the dollar depreciates against the euro, European goods become costlier for American consumers. At the same time, revenues ear...
EVS EVS BROADCAST EQUIPMENT SA
SOLB SOLVAY SA
UCB UCB S.A.
DIE D'IETEREN SA
SIP SIPEF GROUP
SOF SOFINA SA
ASM ASM INTERNATIONAL N.V.
ARCAD ARCADIS NV
ROYAL VOPAK NV
AALB AALBERTS N.V.
MELE MELEXIS NV
KIN KINEPOLIS GROUP NV
ABI ANHEUSER-BUSCH INBEV SA/NV
AD KONINKLIJKE AHOLD DELHAIZE N.V.
ASML ASML HOLDING NV
ARGX ARGEN-X SE
BESI BE SEMICONDUCTOR INDUSTRIES N.V.
ADYEN ADYEN NV
BAR BARCO NV
FUR FUGRO NV
DSFIR KONINKLIJKE DSM N.V.
AGN AEGON N.V.
SYENS SYENSQO
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.